At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
BTRX-246040 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations
In Brief
A Phase 2 clinical trial evaluating BTRX-246040 and Placebo for Parkinson Disease and Motor Disorder. Completed, enrolled 24 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and efficacy of BTRX-246040 in participants with Parkinson's Disease who have motor fluctuations and predictable early morning off periods.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease, Motor Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartAug 2018
Primary CompletionApr 2019
Study CompletionApr 2019
TodayJul 2026
First PostedJul 31, 2018
Enrollment StartAug 31, 2018
Primary CompletionApr 16, 2019
Study CompletionApr 23, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.9 years ago
Interventions
BTRX-246040drug
oral capsule
Placebodrug
oral capsule matching BTRX-246040 capsule